StreetInsider.com News Articles

Truist Securities Reiterates Buy Rating on Cytokinetics (CYTK)

Tue, 01 Sep 2026 03:56:19 -0400

Truist Securities analyst Srikripa Devarakonda reiterated a Buy rating and $112.00 price target on Cytokinetics (NASDAQ: CYTK).

The analyst comments "We reiterate our Buy for CYTK following detailed ACACIA analyses at ESC this past weekend. Despite ACACIA's imbalance in heart failure (4.7% vs. 1.2% pbo), we see a sizable and under-appreciated opportunity with Myqorzo in HCM (we model $5.8B in WW peak rev; 2036E). KOL checks highlight HF as a known side effect of CMIs, ACACIA had no afi-related deaths, improved HF rates with real-world-like use (FOREST-HCM). We believe Myqorzo will likely become the first approved therapy for nHCM (possibly with

Cytokinetics aficamten shows cardiac benefits in two HCM trial analyses

Mon, 31 Aug 2026 06:05:19 -0400

Cytokinetics, Incorporated (Nasdaq: CYTK) announced additional results from two Phase 3 clinical trials of aficamten at the European Society of Cardiology Congress 2026 in Munich, Germany, with findings simultaneously published in Circulation and the Journal of the American College of Cardiology: Heart Failure.

A pre-specified exploratory analysis of the ACACIA-HCM trial, which studied aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM), showed improvements in cardiac structure and diastolic function beyond the previously reported gains in exercise capacity and symptom burden. At 36 weeks and at end of treatment, aficamten significantly improved measures of diastolic function including peak E velocity and

Cytokinetics aficamten shows cardiac benefits in two HCM trial analyses

Mon, 31 Aug 2026 06:05:19 -0400

Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026

Sat, 29 Aug 2026 10:30:00 -0400

Additional Results from ACACIA-HCM Demonstrate Improvements in Cardiac Structure and Diastolic Function in Patients with Non-Obstructive HCM

New Analysis of MAPLE-HCM Finds Aficamten Outperformed Metoprolol Across Pre-Trial Treatment Groups in Patients with Obstructive HCM

SOUTH SAN FRANCISCO, Calif., Aug. 29, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional results from ACACIA-HCM (Assessment Comparing Aficamten to Placebo on Cardiac Endpoints In Adults with Non-Obstructive HCM) and MAPLE-HCM (Metoprolol vs Aficamten in Patients with LVOT Obstruction on Exercise Capacity in HCM) were presented in a Late Breaking Clinical Session at the European

Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026

Sat, 29 Aug 2026 10:30:00 -0400

Additional Results from ACACIA-HCM Demonstrate Improvements in Cardiac Structure and Diastolic Function in Patients with Non-Obstructive HCM

New Analysis of MAPLE-HCM Finds Aficamten Outperformed Metoprolol Across Pre-Trial Treatment Groups in Patients with Obstructive HCM

Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026

Sat, 29 Aug 2026 10:30:00 -0400

Additional Results from ACACIA-HCM Demonstrate Improvements in Cardiac Structure and Diastolic Function in Patients with Non-Obstructive HCM

New Analysis of MAPLE-HCM Finds Aficamten Outperformed Metoprolol Across Pre-Trial Treatment Groups in Patients with Obstructive HCM

Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026

Sat, 29 Aug 2026 10:30:00 -0400

Additional Results from ACACIA-HCM Demonstrate Improvements in Cardiac Structure and Diastolic Function in Patients with Non-Obstructive HCM

New Analysis of MAPLE-HCM Finds Aficamten Outperformed Metoprolol Across Pre-Trial Treatment Groups in Patients with Obstructive HCM

Form 8-K CYTOKINETICS INC For: Aug 28

Fri, 28 Aug 2026 09:22:00 -0400

si-local-file:///var/storage/secattach/20260828/26993767.html

Form 8-K CYTOKINETICS INC For: Aug 28

Fri, 28 Aug 2026 09:22:00 -0400

si-local-file:///var/storage/secattach/20260828/26993767.html

Cytokinetics aficamten meets dual endpoints in non-obstructive HCM trial

Fri, 28 Aug 2026 05:51:41 -0400

Cytokinetics, Incorporated (Nasdaq: CYTK) announced that its Phase 3 ACACIA-HCM clinical trial of aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM) met both dual primary endpoints, according to results presented at the European Society of Cardiology Congress 2026 in Munich, Germany, and simultaneously published in The New England Journal of Medicine.

The trial of 517 participants showed statistically significant improvements from baseline to Week 36 compared to placebo in both the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) and maximal exercise performance (pVO2). The KCCQ-CSS improvement for aficamten versus placebo showed a least square mean difference of 3.0 points

Cytokinetics aficamten meets dual endpoints in non-obstructive HCM trial

Fri, 28 Aug 2026 05:51:41 -0400

Cytokinetics Announces Positive Results from ACACIA-HCM Presented in Hot Line Session at the European Society of Cardiology (ESC) Congress 2026 and Published in The New England Journal of Medicine